Anika Therapeutics, Inc. is a global leader in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid technology to develop differentiated products that address joint pain and tissue repair. It maintains strong partnerships with physicians and distributes its offerings through a mix of direct sales, licensing agreements, and global distributor networks.

The company generates revenue primarily from the sale of its orthopedic and nonorthopedic hyaluronic acid based products. In the United States, its OA Pain Management portfolio, Orthovisc, Monovisc and Cingal, is marketed exclusively by Johnson & Johnson MedTech under long term licensing agreements that provide royalty income. Internationally, these same products are sold directly through a network of commercial distributors. The Regenerative Solutions line, Integrity, Hyalofast and Tactoset, is sold directly to hospitals, ambulatory surgery centers and physicians, with Integrity receiving FDA clearance in 2023 and Hyalofast marketed outside the United States. Nonorthopedic offerings such as Hyvisc for veterinary use, Hyalobarrier as an anti adhesion barrier, and ophthalmic viscoelastics Anikavisc and Nuvisc are distributed via specialty partners worldwide. Additional revenue comes from milestone payments and royalties associated with collaborative development and licensing arrangements.

The company operates through the following segments.

• OA Pain Management: This segment includes Orthovisc, Monovisc and Cingal, which are hyaluronic acid viscosupplements indicated for osteoarthritis pain relief. Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech in the United States under licensing agreements extending through 2031 and 2028 respectively, while Cingal is a single‑injection product combining cross‑linked HA with a steroid and is sold internationally through distributors, with ongoing efforts to secure U. S. FDA approval.

• Regenerative Solutions: This segment comprises Integrity, an HA based scaffold with bone and tendon fixation components cleared by the FDA in August 2023 for rotator cuff and tendon repairs; Hyalofast, a 100% HA resorbable scaffold for cartilage regeneration sold in over 30 countries outside the United States and currently under a pivotal IDE trial for U. S. approval; and Tactoset, an HA enhanced injectable bone substitute used for insufficiency fractures and hardware fixation, marketed principally in the United States.

• Nonorthopedic Products: This segment consists of legacy HA based products for nonorthopedic applications, including Hyvisc, a high molecular weight injectable HA for equine joint dysfunction; Hyalobarrier, an anti adhesion barrier for abdominal pelvic surgeries; and ophthalmic products Anikavisc and Nuvisc, used as viscoelastic agents in cataract and intraocular lens procedures. These products are sold through global commercial sales and marketing partners.

Anika Therapeutics holds a competitive niche within the orthopedic biomaterials market, distinguished by its proprietary hyaluronic acid platform and deep physician relationships. In the OA Pain Management arena, it competes with larger players such as Sanofi Genzyme, Zimmer Biomet, Bioventus, Avanos Medical, Pacira BioSciences, Conmed Corporation and Ferring Pharmaceuticals, yet its Monovisc and Orthovisc products have remained market leaders in the U. S. viscosupplement market since 2018 despite pricing pressures. In Regenerative Solutions, the company faces competition from Arthrex, Smith & Nephew, Stryker, Zimmer Biomet, Atreon Orthopedics and Bone Support AB, but differentiates itself through HA based scaffolds such as Integrity and Hyalofast that offer unique biomechanical properties and a growing body of clinical evidence. Its intellectual property portfolio, ongoing R&D investments and strategic partnerships with distributors and licensing partners further reinforce its market position.

The company serves a diverse customer base that includes orthopedic surgeons, sports medicine physicians, rheumatologists, primary care clinicians, hospital operating rooms, ambulatory surgery centers, veterinary clinics and ophthalmic surgical centers. In the United States, Johnson & Johnson MedTech acts as the exclusive distributor for Monovisc and Orthovisc, while international sales are facilitated by a network of commercial distributors. Regenerative Solutions products are sold directly to hospitals and surgery centers, and nonorthopedic offerings reach veterinarians and ophthalmologists through specialized partners.